Healthcare teamwork placeholder

Our Strategy

How we performed in FY25 against the iHEALTh strategy

Healthcare teamwork placeholder

Our Strategy

How we performed in FY25 against the iHEALTh strategy

Human centred collections

SANBS Purpose Icon

Aspiration

Enhance donor experience through a human centred approach. Enhance brand advocacy

Related material matters

Contribution to long-term sustainable value

Strategic priorities

Increase capacity and capability to collect more blood
Determine true blood demand
Manage deferrals to acceptable levels through strategic initiatives
Ensure improved donor outcomes and excellence and deliver excellence in donor care
Focus on new donors, youth and black donors

Target achieved / exceeded

Improvement YOY

No concerns yet

Below target

Key measured initiatives

Initiative	Target	IR 2023	IR 2024	Progress Apr 2024 - Mar 2025
% Deferrals from all donations	<15.0%	11.1%	10.5%	18.05% There were significant challenges experienced in the calculation required using data from eProgesa compared with Meditech. The calculation required to inform the deferral percentage has been completed. A contributor to the increased deferral rate is the increased number of 1st time donors from new blood drives
#Ferritin testing–- Roll out in Zones (#IronStrong)	Reduce iron deficiency amongst donors	Iron management programme implemented for donors with low ferritin	Digital donor awareness and education through increased social media coverage. New and enhanced quality iron replacement tablets procured	Roll out of Cheliron Forte, an improved iron supplement with fewer side effects, which saw a marked increase in donor uptake
No. of source plasma collections	>=40 000	40 524 63% of target Process of converting group A & AB donors is ongoing to increase Source Plasma collections. This is a long-term project	38 909 60.80% of target Source plasma collection was below target as the focus was on BECS implementation and whole blood and platelets collections. However, the shortfall was offset by recovered plasma from whole blood, ensuring that the overall supply to the National Bioproducts Institute remained on target	39 043 97.6% of target The focus for the year was on increasing Group O stock levels and a sufficient supply of apheresis platelets
Days’ cover (Group O Blood)	5	4.1	3.4 The days covered were below target from December 2023 to March 2024, largely due to some challenges in collections planning encountered after the launch of BECS	6.1 The good growth in blood stock levels resulted from exceptional collection efforts through blood donation drives and donor campaigns
# of units of Apheresis platelets collected	>=22 506	21 121 A strategic project is in place to increase numbers with additional donor centres opened	21 931 99.86% Apheresis platelet collections and pooled platelet production continued to increase	23 281 103.44%
% First time donors aged 16 – 30 years	>70%	71.6% Consistent Y-o-Y growth, primarily attributed to increased accessibility to schools post the pandemic	65.3%	60.9% As part of efforts to expand the donor panel through additional blood drives and a range of local and national promotional activities, the collections from new donors increased to 17.16% over the year. First-time donors aged 16 to 30 rose by 22.73%, from 83 785 to 102 832. However, this age group still represented a smaller proportion of total first-time donors than initially targeted
Percentage collections from Black donors	>=40%	46.7.%	43.2%	46.9%
Social media engagement	95% of target value	74.8% Although numerous posts based on campaigns, engagement levels across all platforms were low	112.8% To attract and retain donors, a targeted social media campaign featuring the SANBS Wellness Support Programme was launched. This initiative leverages an engaging digital series packed with educational, relatable, and easy-to-understand content, driving traffic to our social media pages and website	132.4%
Whole blood collection (Group O)	>=501 764	484 515 Collections for Q4 were 98,13% of target. Did not meet target but collections increased by 26 867 (5,87%) compared to 2021/2022 and 4.18% compared to 2019/2020	475 422 (96.40%) Impact of BECS implementation on collections was significant from November 2023 to January 2024 contributing towards collections for the year being below target	494 851 (98.6%) Group O donations accounted for 50.46% of total collections, below the target of 51.5%. The target was not achieved due to the inability to consistently plan and execute sufficient numbers of blood drives with optimal Group O collections
Innovative ways to collect blood	Ongoing	Various campaigns implemented. Digital donor experience delayed with delayed implementation of BECS	Various campaigns launched and donor questionnaires/registrations have been automated, however there has been a delay in implementing the donor app	The donor app remains a priority for enhancing the user experience

It takes more than one heart to save a life. At SANBS, we serve with heart, together with every donor, every colleague, and every life touched by our mission.